{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:44:46Z","timestamp":1791189886360,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000837","name":"The University of Nottingham","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Stanhope Trust"},{"name":"Multiple Sclerosis Society of Great Britain and Northern Ireland"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.jns.2011.04.024","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T19:05:40Z","timestamp":1306436740000},"page":"127-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Orexin A (hypocretin-1) levels are not reduced while cocaine\/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: No correlation with fatigue and sleepiness"],"prefix":"10.1016","volume":"307","author":[{"given":"Cris S.","family":"Constantinescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Judd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit","family":"Braitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedharan","family":"Harikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Tench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey W.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghatei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2011.04.024_bb0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jns.2011.04.024_bb0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jns.2011.04.024_bb0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/1531-8249(200101)49:1<136::AID-ANA25>3.0.CO;2-M","article-title":"Hypocretin deficiency in familial symptomatic narcolepsy","volume":"49","author":"Melberg","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0020","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0025","doi-asserted-by":"crossref","unstructured":"Goel N, Banks S, Mignot E, Dinges DF. DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness, and fatigue. Neurology 2010;75:1509\u201319.","DOI":"10.1212\/WNL.0b013e3181f9615d"},{"key":"10.1016\/j.jns.2011.04.024_bb0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1212\/01.WNL.0000081049.14098.50","article-title":"CSF hypocretin levels in Guillain\u2013Barre syndrome and other inflammatory neuropathies","volume":"61","author":"Nishino","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.04.024_bb0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/sleep\/26.3.287","article-title":"Decreased hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness","volume":"26","author":"Martinez-Rodriguez","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.jns.2011.04.024_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1191\/135248506ms1320oa","article-title":"Sleep and fatigue in multiple sclerosis","volume":"12","author":"Stanton","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2011.04.024_bb0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archneur.61.4.525","article-title":"The relationship of sleep disturbances and fatigue in multiple sclerosis","volume":"61","author":"Attarian","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0050","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2169\/internalmedicine.42.743","article-title":"Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions","volume":"42","author":"Kato","year":"2003","journal-title":"Intern Med"},{"key":"10.1016\/j.jns.2011.04.024_bb0055","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00415-004-0442-z","article-title":"Low CSF hypocretin-1\/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis","volume":"251","author":"Oka","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2869.2003.00333.x","article-title":"CSF hypocretin (orexin) in neurological and psychiatric conditions","volume":"12","author":"Ebrahim","year":"2003","journal-title":"J Sleep Res"},{"key":"10.1016\/j.jns.2011.04.024_bb0065","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/jnen\/60.12.1208","article-title":"Hypothalamic lesions in multiple sclerosis","volume":"60","author":"Huitinga","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0070","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/1352458509350306","article-title":"Hypothalamic involvement assessed by T1 relaxation time in patients with relapsing remitting multiple sclerosis","volume":"15","author":"Zellini","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2011.04.024_bb0075","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0166-2236(98)01377-0","article-title":"CART peptides: novel addiction- and feeding-related neuropeptides","volume":"22","author":"Kuhar","year":"1999","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jns.2011.04.024_bb0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0085","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.04.024_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-5793(99)01030-3","article-title":"Distribution and quantification of immunoreactive orexin A in rat tissues","volume":"457","author":"Taheri","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jns.2011.04.024_bb0095","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1210\/jc.2007-1946","article-title":"Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy","volume":"93","author":"Bech","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jns.2011.04.024_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-8981(72)90410-X","article-title":"Etude quantitative des immunoglobulins G et de l'albumine du liquide cephalo-rachidien","volume":"37","author":"Delpech","year":"1972","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jns.2011.04.024_bb0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/00365517709091498","article-title":"Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis","volume":"37","author":"Link","year":"1977","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jns.2011.04.024_bb0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archneur.1988.00520280085020","article-title":"Fatigue in multiple sclerosis","volume":"45","author":"Krupp","year":"1988","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0115","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"10.1016\/j.jns.2011.04.024_bb0120","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.04.024_bb0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pmr.2005.01.014","article-title":"Multiple sclerosis-related fatigue","volume":"16","author":"MacAllister","year":"2005","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.jns.2011.04.024_bb0130","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","article-title":"Low levels of ventricular CSF orexin\/hypocretin in advanced PD","volume":"61","author":"Drouot","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.04.024_bb0135","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jnnp.2005.067207","article-title":"Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy","volume":"77","author":"Baumann","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2011.04.024_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp.74.1.127","article-title":"Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia","volume":"74","author":"Ebrahim","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2011.04.024_bb0145","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1440-1819.2002.00974.x","article-title":"Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain\u2013Barre syndrome","volume":"56","author":"Kanbayashi","year":"2002","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jns.2011.04.024_bb0150","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","article-title":"CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions","volume":"57","author":"Ripley","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.04.024_bb0155","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/1352458508088939","article-title":"Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing\u2013remitting multiple sclerosis and monosymptomatic optic neuritis","volume":"14","author":"Knudsen","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2011.04.024_bb0160","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ng.372","article-title":"Narcolepsy is strongly associated with the T-cell receptor alpha locus","volume":"41","author":"Hallmayer","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jns.2011.04.024_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.psychres.2007.06.031","article-title":"Cocaine and amphetamine regulated transcript (CART) in suicide attempters","volume":"158","author":"Brundin","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jns.2011.04.024_bb0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2008.04.011","article-title":"Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt","volume":"113","author":"Brundin","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jns.2011.04.024_bb0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1474-4422(08)70140-6","article-title":"CSF hypocretin-1 assessment in sleep and neurological disorders","volume":"7","author":"Bourgin","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jns.2011.04.024_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2006.07.009","article-title":"International quality control survey of neurochemical dementia diagnostics","volume":"409","author":"Lewczuk","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2011.04.024_bb0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jim.2009.09.014","article-title":"Neurofilament ELISA validation","volume":"352","author":"Petzold","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jns.2011.04.024_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neulet.2010.02.062","article-title":"CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients","volume":"474","author":"Papuc","year":"2010","journal-title":"Neurosci Lett"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11002279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11002279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:40:45Z","timestamp":1758382845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X11002279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0022510X11002279"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2011.04.024","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orexin A (hypocretin-1) levels are not reduced while cocaine\/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: No correlation with fatigue and sleepiness","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2011.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}